Le Lézard
Classified in: Health, Science and technology
Subjects: Conference, Trade Show

Newron Pharmaceuticals to Present at the 22nd Annual BIO CEO & Investor Conference in New York


Newron Pharmaceuticals S.p.A. ("Newron") (SIX: NWRN, XETRA: NP5), a biopharmaceutical company focused on the development of novel therapies for patients with diseases of the central and peripheral nervous system, today announced that Stefan Weber, CEO, will present at the 22nd Annual BIO CEO & Investor Conference in New York, NY on Tuesday, February 11, 2020 at 11:00 a.m. ET in the Odets room (4th floor) at the New York Marriott Marquis.

BIO CEO & Investor Conference is one of the largest independent investor conferences focused on established and emerging publicly traded and select private biotech companies. Sponsored by the Biotechnology Innovation Organization, the world's largest biotech trade association, BIO CEO provides a forum where institutional investors, industry analysts and senior biotechnology executives have the opportunity to shape the future investment landscape of the biotechnology industry.

About Newron Pharmaceuticals

Newron (SIX: NWRN, XETRA: NP5) is a biopharmaceutical company focused on the development of novel therapies for patients with diseases of the central and peripheral nervous system. The Company is headquartered in Bresso near Milan, Italy. Xadago®/safinamide has received marketing authorization for the treatment of Parkinson's disease in the European Union, Switzerland, the USA, Australia, Canada, Brazil, Colombia, the United Arab Emirates and Japan, and is commercialized by Newron's Partner Zambon. US WorldMeds holds the commercialization rights in the USA. Meiji Seika has the rights to develop and commercialize the compound in Japan and other key Asian territories. In addition to Xadago®/safinamide for Parkinson's disease, Newron has a strong pipeline of promising treatments for rare disease patients at various stages of clinical development, including sarizotan for patients with Rett syndrome and ralfinamide for patients with specific rare pain indications. Newron is also developing Evenamide as the potential first add-on therapy for the treatment of patients with positive symptoms of schizophrenia. For more information, please visit: www.newron.com?


These press releases may also interest you

at 20:50
Overture Launches Inner Circles: Redefining Private Attorney Referral Networks
Overture.law, the nation's leading attorney-to-attorney referral platform, launches their transformative new product, Inner Circles. This groundbreaking product empowers attorneys, law schools, bar associations, and affinity groups to build private...

at 20:09
Not Just 1, But 2: BASIS Charter Schools Celebrates a Pair of Students Named Presidential Scholars by the U.S. Department of Education
BASIS Charter Schools proudly announce that two of its exceptional students have been named 2024 U.S. Presidential Scholars by the U.S. Department of Education. Matteo N. Huish from BASIS Mesa and Sruti Peddi from BASIS Scottsdale have been...

at 20:00
Greenberg Traurigs Kemal Hawa to Moderate Panel at DICE East 2024
Kemal Hawa, co-chair of the Digital Infrastructure, Data Center and Cloud Computing Practice of global law firm Greenberg Traurig, LLP, will moderate a panel at DICE East 2024 May 22 in Reston, Virginia. Hawa, a member of the firm's Washington,...

at 19:45
WIO Taps Gracenote to Revolutionize Television Broadcast Reporting
WIO LLC, parent company of the global TV broadcast airings platform, WIOprotm, has announced a new strategic agreement with Gracenote, the global content data business unit of Nielsen, to address the longstanding challenge of accurately tracking and...

at 19:35
Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Mirum Pharmaceuticals, Inc. today announced that on May 10, 2024, the Compensation Committee of Mirum's Board of Directors granted inducement awards consisting of non-qualified stock options to purchase 38,600 shares of common stock and 19,300...

at 19:00
Evolus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Evolus, Inc. , a performance beauty company with a focus on building an aesthetic portfolio of consumer brands, today reported the grant of non-qualified stock options to purchase an aggregate of 10,990 shares of Evolus and an aggregate of 42,759...

More news about Science and technology...


News published on and distributed by: